Increased expression of PD-1 in CD8 + CD3 + T cells correlates with EBV viral load in MS patients

Najmadini, Atefeh; Langroudi, Ladan; Meimand, Hossein Ali Ebrahimi; Mahmoodi, Merat; Mirzaei, Mahboubeh

doi:10.1007/s13365-022-01083-2

J. Neurovirol.

2022

DOI: 10.1007/s13365-022-01083-2

|View full text |Cite

Increased expression of PD-1 in CD8 + CD3 + T cells correlates with EBV viral load in MS patients

Atefeh Najmadini

Ladan Langroudi

Hossein Ali Ebrahimi Meimand³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice

Daei Sorkhabi,

Komijani,

Sarkesh

et al. 2023

Cell Commun Signal

View full text Add to dashboard Cite

Beyond the encouraging results and broad clinical applicability of immune checkpoint (ICP) inhibitors in cancer therapy, ICP-based immunotherapies in the context of autoimmune disease, particularly multiple sclerosis (MS), have garnered considerable attention and hold great potential for developing effective therapeutic strategies. Given the well-established immunoregulatory role of ICPs in maintaining a balance between stimulatory and inhibitory signaling pathways to promote immune tolerance to self-antigens, a dysregulated expression pattern of ICPs has been observed in a significant proportion of patients with MS and its animal model called experimental autoimmune encephalomyelitis (EAE), which is associated with autoreactivity towards myelin and neurodegeneration. Consequently, there is a rationale for developing immunotherapeutic strategies to induce inhibitory ICPs while suppressing stimulatory ICPs, including engineering immune cells to overexpress ligands for inhibitory ICP receptors, such as program death-1 (PD-1), or designing fusion proteins, namely abatacept, to bind and inhibit the co-stimulatory pathways involved in overactivated T-cell mediated autoimmunity, and other strategies that will be discussed in-depth in the current review.

show abstract

Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice

Daei Sorkhabi,

Komijani,

Sarkesh

et al. 2023

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Increased expression of PD-1 in CD8 + CD3 + T cells correlates with EBV viral load in MS patients

Cited by 1 publication

References 46 publications

Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice

Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice

Contact Info

Product

Resources

About